Publication | Open Access
Two-Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMD
315
Citations
19
References
2007
Year
In these postmenopausal women with low BMD, treatment with denosumab for 2 yr was associated with sustained increases in BMD and reductions in bone resorption markers compared with placebo.
| Year | Citations | |
|---|---|---|
Page 1
Page 1